🔎 Trials Near Me

Acasă › Neuroblastom › Texas

Studii clinice pentru Neuroblastom în Texas

15 studii pentru Neuroblastom caută participanți în Texas.

Orașe în Texas

Text oficial al studiului (în engleză)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • Medical City Dallas Hospital, Dallas
  • și încă 10
În curs de recrutareFaza 3
Până la vârsta de 30 · Toate sexele · Actualizat 2 oct. 2026 · NCT06172296

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • University of Texas MD Anderson Cancer Center ( Site 1007), Houston
În curs de recrutareFaza 1/2
6 Months – 25 Years · Toate sexele · Actualizat 17 sept. 2026 · NCT06395103

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

  • Dell Children's Blood and Cancer Center, Austin
  • Children's Medical Center, Dallas
În curs de recrutareFaza 2
Până la vârsta de 22 · Toate sexele · Actualizat 4 sept. 2026 · NCT02559778

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

  • Children's Medical Center, Dallas
În curs de recrutareFaza 1/2
Până la vârsta de 26 · Toate sexele · Actualizat 3 sept. 2026 · NCT06465199

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • Children's Medical Center, Dallas
În curs de recrutareFaza 1/2
Până la vârsta de 30 · Toate sexele · Actualizat 3 sept. 2026 · NCT06541262

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

  • Dell Children's Blood and Cancer Center, Austin
  • Children's Medical Center, Dallas
În curs de recrutareFaza 2
Vârste de la 1 la 21 · Toate sexele · Actualizat 3 sept. 2026 · NCT06540963

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • și încă 8
În curs de recrutareFaza 3
365 Days – 30 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
În curs de recrutareFaza 1/2
12 Months – 30 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT04851119

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

  • Dell Children's Blood and Cancer Center, Austin
În curs de recrutareFaza 2
12 Months – 21 Years · Toate sexele · Actualizat 12 aug. 2026 · NCT05489887

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

  • Texas Children's Hospital, Houston
În curs de recrutareFaza 1/2
Vârste de la 1 la 30 · Toate sexele · Actualizat 22 iul. 2026 · NCT06721689

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

  • Texas Children's Hospital, Houston
În curs de recrutareFaza 1
Vârste de la 1 la 24 · Toate sexele · Actualizat 21 iul. 2026 · NCT07211737

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

  • University of Texas Southwestern, Dallas
  • Cook Children's Medical Center, Fort Worth
În curs de recrutareFaza 2
Vârste de la 1 la 31 · Toate sexele · Actualizat 20 iul. 2026 · NCT06450041

Neuroblastoma Biology Study

  • University of Texas Southwestern, Dallas
  • Cook Children's Medical Center - Fort Worth, Fort Worth
În curs de recrutareStudiu observațional
31 Days – 99 Years · Toate sexele · Actualizat 23 mar. 2026 · NCT01587300

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

  • University of Texas Southwestern Medical Center, Dallas
În curs de recrutare
Până la vârsta de 17 · Toate sexele · Actualizat 10 feb. 2026 · NCT06831552

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma

  • Texas Children's Hospital, Houston
În curs de recrutareFaza 1
Vârste de la 1 la 21 · Toate sexele · Actualizat 19 sept. 2025 · NCT03294954

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.